title: In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody.
abstract: Small recombinant antibody fragments (e.g. scFvs and VHHs), which are highly tissue permeable, are being investigated for antivenom production as conventional antivenoms consisting of IgG or F(ab')2 antibody fragments do not effectively neutralize venom toxins located in deep tissues. However, antivenoms composed entirely of small antibody fragments may have poor therapeutic efficacy due to their short serum half-lives. To increase serum persistence and maintain tissue penetration, we prepared low and high molecular mass antivenom antibodies. Four llama VHHs were isolated from an immune VHH-displayed phage library and were shown to have high affinity, in the low nM range, for α-cobratoxin (α-Cbtx), the most lethal component of Naja kaouthia venom. Subsequently, our highest affinity VHH (C2) was fused to a human Fc fragment to create a VHH2-Fc antibody that would offer prolonged serum persistence. After in planta (Nicotiana benthamiana) expression and purification, we show that our VHH2-Fc antibody retained high affinity binding to α-Cbtx. Mouse α-Cbtx challenge studies showed that our highest affinity VHHs (C2 and C20) and the VHH2-Fc antibody effectively neutralized lethality induced by α-Cbtx at an antibody:toxin molar ratio as low as ca. 0.75×:1. Further research towards the development of an antivenom therapeutic involving these anti-α-Cbtx VHHs and VHH2-Fc antibody molecules should involve testing them as a combination, to determine whether they maintain tissue penetration capability and low immunogenicity, and whether they exhibit improved serum persistence and therapeutic efficacy.
authors.affiliation: School of Environmental Sciences, University of Guelph, Guelph, Ontario, Canada.
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Richard
authors.forename: Ashley J
authors.initials: AJ
authors.lastname: Meyers
authors.forename: Michael D
authors.initials: MD
authors.lastname: McLean
authors.forename: Mehdi
authors.initials: M
authors.lastname: Arbabi-Ghahroudi
authors.forename: Roger
authors.initials: R
authors.lastname: MacKenzie
authors.forename: J Christopher
authors.initials: JC
authors.lastname: Hall
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D057134:Antibodies, Neutralizing / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000915:Antibody Affinity; D002161:Camelids, New World; D003039:Cobra Neurotoxin Proteins / Q000276:immunology*; D004546:Elapid Venoms / Q000276:immunology; D006207:Half-Life; D006801:Humans; D056724:Immunity, Humoral; D007114:Immunization; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D007700:Kinetics; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D061905:Single-Domain Antibodies / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D003039:Cobra Neurotoxin Proteins; D004546:Elapid Venoms; D007141:Immunoglobulin Fc Fragments; C521753:Naja kaouthia venom; D011993:Recombinant Fusion Proteins; D061905:Single-Domain Antibodies; C025154:alpha-cobratoxin
references.citation: Plant Biotechnol J. 2009 Jun;7(5):442-55
references.pmid: 19422604
references.citation: J Proteomics. 2009 Mar 6;72(2):270-82
references.pmid: 19162253
references.citation: Mol Immunol. 2008 Aug;45(14):3847-56
references.pmid: 18614235
references.citation: Immunotechnology. 1997 Jun;3(2):117-25
references.pmid: 9237096
references.citation: J Biol Chem. 2011 Mar 18;286(11):8961-76
references.pmid: 21216961
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14701-6
references.pmid: 16973752
references.citation: Toxicon. 1998 Nov;36(11):1529-38
references.pmid: 9792169
references.citation: Toxicon. 2005 Dec 1;46(7):775-81
references.pmid: 16183094
references.citation: FASEB J. 2010 Sep;24(9):3479-89
references.pmid: 20410443
references.citation: Methods Mol Biol. 2009;525:187-216, xiii
references.pmid: 19252860
references.citation: J Immunol. 1991 Sep 1;147(5):1709-19
references.pmid: 1908882
references.citation: J Agric Food Chem. 2010 Sep 22;58(18):10056-63
references.pmid: 20799692
references.citation: Toxicon. 2010 Sep 1;56(3):363-72
references.pmid: 20362604
references.citation: Toxicon. 2010 Feb-Mar;55(2-3):642-5
references.pmid: 19647761
references.citation: Nature. 1993 Jun 3;363(6428):446-8
references.pmid: 8502296
references.citation: Toxicon. 2006 Mar;47(3):364-8
references.pmid: 16359717
references.citation: Biochim Biophys Acta. 1999 Apr 12;1431(1):37-46
references.pmid: 10209277
references.citation: Mol Immunol. 2008 Aug;45(14):3703-13
references.pmid: 18632156
references.citation: Toxicon. 2010 Sep 1;56(3):373-80
references.pmid: 20412814
references.citation: Int J Cancer. 2002 Mar 20;98(3):456-62
references.pmid: 11920600
references.citation: Methods Mol Biol. 2012;911:257-75
references.pmid: 22886257
references.citation: Cancer Res. 2004 Apr 15;64(8):2853-7
references.pmid: 15087403
references.citation: Mol Immunol. 1992 Apr;29(4):501-10
references.pmid: 1565098
references.citation: Plant Biotechnol J. 2009 Jan;7(1):59-72
references.pmid: 18793269
references.citation: Biochem J. 2009 Nov 11;424(2):263-72
references.pmid: 19732033
references.citation: Mol Immunol. 2000 Aug;37(10):579-90
references.pmid: 11163394
references.citation: J Mol Biol. 2005 Jul 1;350(1):112-25
references.pmid: 15913651
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3322-8
references.pmid: 17606688
references.citation: J Immunol Methods. 2011 Oct 28;373(1-2):8-18
references.pmid: 21777591
references.citation: Toxicon. 1972 May;10(3):217-25
references.pmid: 5072086
references.citation: Bull World Health Organ. 1998;76(5):515-24
references.pmid: 9868843
references.citation: Nat Biotechnol. 2005 Jun;23(6):718-23
references.pmid: 15883585
references.citation: Clin Pharmacokinet. 2003;42(8):721-41
references.pmid: 12846594
references.citation: Vaccine. 1997 Oct;15(14):1523-8
references.pmid: 9330463
references.citation: J Biol Chem. 2011 Jun 10;286(23):20892-900
references.pmid: 21489992
references.citation: FASEB J. 2002 Feb;16(2):240-2
references.pmid: 11772942
references.citation: J Immunol Methods. 2010 Aug 31;360(1-2):103-18
references.pmid: 20600077
references.citation: J Toxicol Clin Toxicol. 2003;41(3):277-90; 317-27
references.pmid: 12807311
references.citation: J Immunol Methods. 2000 Jun 23;240(1-2):185-95
references.pmid: 10854612
references.citation: Nat Struct Biol. 1996 Sep;3(9):803-11
references.pmid: 8784355
references.citation: Toxicon. 2001 Oct;39(10):1487-94
references.pmid: 11478956
references.citation: EMBO J. 1998 Jul 1;17(13):3512-20
references.pmid: 9649422
references.citation: PLoS Med. 2006 Jun;3(6):e150
references.pmid: 16729843
references.citation: Biochimie. 2000 Sep-Oct;82(9-10):841-50
references.pmid: 11086214
references.citation: Mol Immunol. 2010 Apr;47(7-8):1529-34
references.pmid: 20153529
references.citation: Curr Pharm Des. 2007;13(28):2935-50
references.pmid: 17979738
references.citation: Toxicon. 2003 Dec;42(7):785-91
references.pmid: 14757210
references.citation: Mol Immunol. 1997 Nov-Dec;34(16-17):1121-31
references.pmid: 9566760
references.citation: FEBS Lett. 1997 Sep 15;414(3):521-6
references.pmid: 9323027
references.citation: Toxicon. 2007 Apr;49(5):699-709
references.pmid: 17257638
references.citation: J Biol Chem. 2011 Feb 25;286(8):6143-51
references.pmid: 21156801